Bank of New York Mellon’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $107M | Sell |
|
|||||
|
2025
Q2 | $97.9M | Sell |
|
|||||
|
2025
Q1 | $91.7M | Sell |
|
|||||
|
2024
Q4 | $119M | Buy |
|
|||||
|
2024
Q3 | $98.9M | Sell |
|
|||||
|
2024
Q2 | $129M | Buy |
|
|||||
|
2024
Q1 | $127M | Sell |
|
|||||
|
2023
Q4 | $129M | Sell |
|
|||||
|
2023
Q3 | $173M | Sell |
|
|||||
|
2023
Q2 | $150M | Sell |
|
|||||
|
2023
Q1 | $167M | Sell |
|
|||||
|
2022
Q4 | $201M | Sell |
|
|||||
|
2022
Q3 | $185M | Buy |
|
|||||
|
2022
Q2 | $166M | Buy |
|
|||||
|
2022
Q1 | $160M | Sell |
|
|||||
|
2021
Q4 | $159M | Sell |
|
|||||
|
2021
Q3 | $182M | Sell |
|
|||||
|
2021
Q2 | $196M | Buy |
|
|||||
|
2021
Q1 | $188M | Buy |
|
|||||
|
2020
Q4 | $112M | Buy |
|
|||||
|
2020
Q3 | $107M | Buy |
|
|||||
|
2020
Q2 | $119M | Buy |
|
|||||
|
2020
Q1 | $71.2M | Buy |
|
|||||
|
2019
Q4 | $67.6M | Sell |
|
|||||
|
2019
Q3 | $83.6M | Sell |
|
|||||
|
2019
Q2 | $80.5M | Sell |
|
|||||
|
2019
Q1 | $84.1M | Sell |
|
|||||
|
2018
Q4 | $69.2M | Sell |
|
|||||
|
2018
Q3 | $124M | Sell |
|
|||||
|
2018
Q2 | $120M | Sell |
|
|||||
|
2018
Q1 | $111M | Sell |
|
|||||
|
2017
Q4 | $115M | Sell |
|
|||||
|
2017
Q3 | $112M | Sell |
|
|||||
|
2017
Q2 | $101M | Buy |
|
|||||
|
2017
Q1 | $82.5M | Buy |
|
|||||
|
2016
Q4 | $54.2M | Sell |
|
|||||
|
2016
Q3 | $71.2M | Buy |
|
|||||
|
2016
Q2 | $18.9M | Sell |
|
|||||
|
2016
Q1 | $17.9M | Buy |
|
|||||
|
2015
Q4 | $25.1M | Buy |
|
|||||
|
2015
Q3 | $16.6M | Sell |
|
|||||
|
2015
Q2 | $22.6M | Buy |
|
|||||
|
2015
Q1 | $17.3M | Buy |
|
|||||
|
2014
Q4 | $8.67M | Sell |
|
|||||
|
2014
Q3 | $6.1M | Buy |
|
|||||
|
2014
Q2 | $5.49M | Buy |
|
|||||
|
2014
Q1 | $5.91M | Buy |
|
|||||
|
2013
Q4 | $3.25M | Buy |
|
|||||
|
2013
Q3 | $3.86M | Sell |
|
|||||
|
2013
Q2 | $6.82M | Buy |
|